Join

Compare · LHDX vs MDT

LHDX vs MDT

Side-by-side comparison of Lucira Health Inc. (LHDX) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both LHDX and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
  • MDT is the larger of the two at $106.97B, about 518.5x LHDX ($206.3M).
  • MDT has hit the wire 7 times in the past 4 weeks while LHDX has been quiet.
  • MDT has more recent analyst coverage (25 ratings vs 0 for LHDX).
MetricLHDXMDT
Company
Lucira Health Inc.
Medtronic plc.
Price
$0.45-19.60%
$83.32-0.55%
Market cap
$206.3M
$106.97B
1M return
-
-5.21%
1Y return
-
-0.81%
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NASDAQ
NYSE
IPO
2021
News (4w)
0
7
Recent ratings
0
25
LHDX

Lucira Health Inc.

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.

MDT

Medtronic plc.

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Latest LHDX

Latest MDT